Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
“These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
“Although these infiltrates of inflammatory cells can vary in size and composition from tumor to tumor, their presence has been taken as evidence that the host is not ignorant of the developing tumor, but rather attempts to interfere with tumor progression, a process referred to as immune surveillance (Zitvogel et al.,…”
BackgroundInfluentialTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
“Cancer cells differ from healthy cells due to a plethora of molecular changes (Hanahan and Weinberg, 2000; Zitvogel et al., 2006), many of which may be mechanistically linked to metabolic reprogramming (Figure 3).”
BackgroundSelf-citationNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
“In support of cancer immunosurveillance is the fact that both immunodeficient or immunosuppressed patients and experimental animals are more susceptible to tumor development (for reviews see Dunn et al., 2004; Zitvogel et al., 2006; Swann and Smyth, 2007).”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
“Indeed, for the development of full-blown neoplasia , cancer cells have to overcome intrinsic (cell autonomous) and extrinsic (immune mediated) barriers to oncogenesi”
BackgroundSelf-citationImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
“Malignant lesions attempting to escape immunosurveillance harness such system to establish robust immunosuppressive networks (Zitvogel et al., 2006).”
BackgroundTranslational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
“More problematically, many tumors, including neuroblastoma, evade T cell immune responses by downregulating their MHC expression or by degrading their antigen-processing mechanism”
BackgroundImmune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
“Therefore, it is time to propose the immune reaction as a seventh hallmark of cancer, as proposed by Zitvogel et al. (2006), and to integrate the analysis and quantification of immune infiltrates as a routine prognostic factor.”
BackgroundNivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
“Multiple resistance mechanisms, including systemic dysfunction in T-cell signaling(4-7) and exploitation of immune checkpoints,(8) evolve in tumors, helping them evade specific immune responses despite the presentation of tumor antigens to the immune system.(8) Recent understanding of these host-tumor immune interacti…”
BackgroundDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
“lesions should trigger vigorous immune responses (1, 52), such as that observed in patientswith premalignantmonoclonal gammopathy (53).”
BackgroundAllen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826
“In the gut, myeloidderived cells also act as tumor associated antigenpresenting cells and are responsible for efficient phagocytosis and removal of apoptotic/tumorigenic cells (Zitvogel et al., 2006).”
BackgroundKryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
“Interestingly, LPS and especially accidental necrotic cells stimulated the production of IL-10 (Figure 1D), whereas Hyp-PDT-treated cells failed to stimulate the production of this immunosuppressive cytokine (Kim et al , 2006; Zitvogel et al , 2006) by hu-iDCs.”
Sharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
“Under these chronically IDO-deficient conditions, tumors showed a compensatory increase in the form of Treg activity that was not dependent on IDO, consistent with emergence of tumor escape variants (36).”
BackgroundInterleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.240 · Cited by 777
“For example, tumor growth promotes the expansion of Tregs and Tregs could suppress NK cell functions including cytotoxicity, NKG2D expression, and IFN- production in human and mice (21, 22).”
BackgroundChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
The head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 765
“Collectively, these influences permit immunosubversion (50).”
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
“Tumour cells employ many different strategies to evade immunosurveillance by NK cells (Zitvogel et al., 2006).”
BackgroundCancers Complicating Inflammatory Bowel Disease
Beaugerie, L., & Itzkowitz, S. H. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403718 · Cited by 678
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
“Escape can result from active suppression of immune effectors, (immunosubversion), or from the loss of antigenic properties (immunoevasion)”
BackgroundThe Malassezia Genus in Skin and Systemic Diseases
Gaitanis, G., Magiatis, P., Hantschke, M., Bassukas, I. D., & Velegraki, A. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-11 · Cited by 642
“In the pathogenesis of basal cell carcinomas, activating mutations of the hedgehog pathway at the cellular level are implicated (94, 154), while at the tissue level, they act together with the induction of immune tolerance by the establishing tumor (immunosubversion) (172, 178, 352).”
BackgroundImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
“In fact, successful escape from immune surveillance is considered one of the necessary hallmarks of cance”
BackgroundTH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
“In a rather simplified view, tumor-induced immune subversion results from two main activities, namely the induction of tolerance toward tumor antigens and the functional suppression of the effector lymphocytes that normally counteract tumor growth (1, 2, 13, 14).”
BackgroundDeciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
“The prohibitive nature of the tumor endothelium can be mediated by the type and quantity of adhesion molecules expressed (Zitvogel et al., 2006) and is presumably maintained by local soluble tumor factors (Zitvogel et al., 2006), but precisely how the tumor vasculature establishes immune privilege…”
InfluentialGilboa, E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31205 · Cited by 588
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
“The findings discussed in this review unravel several novel facets of the concept of tumor immunosurveillance (57).”
BackgroundThe anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
“The therapeutic effect of IL-12 was attributed to enhancing cytolytic activity of NK and CD8þ T cells (6) and of stimulating a subset of NKp46þ cells (18).”
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Tregs and rethinking cancer immunotherapy
Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 547
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
“…investigating the role of anti-tumour immunity by T cells, this model could be adapted to investigate the role of other critical immune cells in cancer immunoediting, such as B cells or NK cells, by either introducing surface-expressed or stress-related antigens into tumours, respectively 18–20 .”
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 512
“Tumor cells express molecules and release mediators (12) that allow their evasion from NK cells immunosurveillance (13).”
BackgroundImmunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Zhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., & Zhang, X.-Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02786 · Cited by 498
Molecular characteristics of immunogenic cancer cell death
Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402269 · Cited by 494
“has been suggested that cancer cells also have the capacity to evade the surveillance by the immune system.(32) Therefore, it would be of highest therapeutic value to restore the immune”
BackgroundClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
“Finally, we obtained evidence indicating that the host immune system can recognize (and sometimes react against) (pre-) malignant cells as they transform, proliferate, evolve and respond to therapy, founding the theoretical grounds of anticancer immunosurveillance [15-17].”
BackgroundAxelrad, J. E., Lichtiger, S., & Yajnik, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i20.4794 · Cited by 431
Placke, T., Örgel, M., Schaller, M., Jung, G., Rammensee, H.-G., Kopp, H.-G., & Salih, H. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1872 · Cited by 458
“Although counterintuitive from the "missing self" principle of NK cell activation (11, 12), tumor cells often downregulate MHC class I, likely to evade T-cell– mediated immunosurveillance (32).”
BackgroundTGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458
Nutrition, inflammation and cancer
Zitvogel, L., Pietrocola, F., & Kroemer, G. (2017) · Nature Immunology · doi:10.1038/ni.3754 · Cited by 446
Self-citationCell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
The determinants of tumour immunogenicity
Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3246 · Cited by 441
Biswas, S. K., Sica, A., & Lewis, C. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2011 · Cited by 435
“A large body of evidence shows that once tumors start to develop TAM exhibit an immunosuppressive phenotype, with their ability to present tumor-associated Ags, lyse tumor cells, and stimulate the antitumor functions of T cells and NK cells being suppressed (8, 17).”
BackgroundHalama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
“The role of specific immune cell subpopulations and the role of the immune system in mediating response or resistance to conventional chemotherapy in metastatic CRC is also not clear (15).”
BackgroundNew insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
Di Biase, S., Lee, C., Brandhorst, S., Manes, B., Buono, R., Cheng, C.-W., Cacciottolo, M., Martin-Montalvo, A., de Cabo, R., Wei, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.005 · Cited by 404
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
“Primary tumors can often be completely removed with current cancer therapeutic modalities; however, micrometastases of dormant tumor cells frequently lead to the establishment of the distant metastases and to the relapse of the disease (1).”
BackgroundAbsence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Paczulla, A. M., Rothfelder, K., Raffel, S., Konantz, M., Steinbacher, J., Wang, H., Tandler, C., Mbarga, M., Schaefer, T., Falcone, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1410-1 · Cited by 391
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
The interplay between immunosenescence and age-related diseases
Barbé-Tuana, F., Funchal, G., Schmitz, C. R. R., Maurmann, R. M., & Bauer, M. E. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00806-z · Cited by 384
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
“Tumors employ several mechanisms to avoid or actively suppress anticancer immune responses (1, 2).”
BackgroundSelf-citationBremnes, R. M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., Camps, C., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182037b76 · Cited by 369
Protumor vs Antitumor Functions of IL-17
Murugaiyan, G., & Saha, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901017 · Cited by 369
Chew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K. H., Weber, A., Slankamenac, K., Poon, R. T. P., Yang, H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300509 · Cited by 359
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
“These and other factors facilitate tumor relapse, despite high numbers of circulating tumor-specific T cells (10, 11).”
BackgroundThe integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi-Galy, S. I., Goddard-Leon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 345
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344
“T major obstacle to defining an efficient immunotherapy protocol for the treatment of solid tumors is the capacity of the tumor microenvironment (TME) to inhibit the host immune response at both the local and systemic levels (1).”
BackgroundImmunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
“The importance of cancer immunosurveillance against cancer is controversial (Zitvogel et al, 2006) but may have a role in controlling the stepwise progression of multiple myeloma from a premalignant clone to active myeloma and the escape from plateau phase.”
BackgroundEmerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz-Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.99 · Cited by 341
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
“For example, induction of regulatory T cells (Tregs) or myeloid suppressor cells and/or production of several immunosuppressive factors [including arginase-1, NOS-2, IDO, or TGF- ] by tumor cells or components of tumor microenvironment may result in functional subversion of tumor-infiltrating immunocompetent cells (27…”
BackgroundInfluentialRavi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
“Tumors unresponsive to the immunogenic actions of cyclophosphamide may be deficient in factors essential for ICD, such as stress ligands like MHC class I [23], or may express factors that confer resistance to ICD, such as PD-L1 [48].”
BackgroundImmunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
“It is now clear that naı̈ve tumor cells can be effectively eliminated by the immune system except for those that successfully dodge the immune attack and establish an immunosuppressive microenvironment.(1,2,5,6) During this process, tumor cells initiate pathological manifestations and eventually become malignant.”
BackgroundNatural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 310
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
“Tumor cells share many characteristics, such as enabling replicative immortality, evading cell death, escaping the host immune system, and others [2–5].”
BackgroundFollowing TRAIL’s path in the immune system
Falschlehner, C., Schaefer, U., & Walczak, H. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03058.x · Cited by 299
Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297
“Tumour-associated macrophages (TAMs) Release of arginase-1, IL-10, TGFb and PDE2 Inhibition of T-cell function, promotion of Th2-cell response [167]”
BackgroundInfluentialRaf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
“More recently, the list has been revised to include other features of cancer cells related to their interaction with the environment, such as avoidance of immunosurveillance (Dunn et al., 2004; Smyth et al., 2006; Zitvogel et al., 2006) and the stress phenotypes of cancer (Luo et al.”
BackgroundDPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis
Okondo, M. C., Johnson, D. C., Sridharan, R., Go, E. B., Chui, A. J., Wang, M. S., Poplawski, S. E., Wu, W., Liu, Y., Lai, J. H., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2229 · Cited by 290
p21 produces a bioactive secretome that places stressed cells under immunosurveillance
Sturmlechner, I., Zhang, C., Sine, C. C., van Deursen, E.-J., Jeganathan, K. B., Hamada, N., Grasic, J., Friedman, D., Stutchman, J. T., Can, I., et al. (2021) · Science · doi:10.1126/science.abb3420 · Cited by 295
“complementing established tumor-protective actions of immune cells based on the expression of tumor-specific neoantigens (32).”
BackgroundRelevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01586-y · Cited by 278
“This highly trafficked network constitutes the tumor microenvironment (TME) (Fig.”
BackgroundInfluentialThe genomic landscape of breast cancer and its interaction with host immunity
Luen, S., Virassamy, B., Savas, P., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 277
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
“immature DCs and pDCs, and MDSCs has been demonstrated to be pivotal for the induction and ⁄or maintenance of local immune privilege in a number of animal models (34, 36, 37).”
BackgroundGarg, A. D., & Agostinis, P. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c3pp50333j · Cited by 276
Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276
“The T cell response and the tumor growth will probably reach an equilibrium.(71) This equilibrium is broken when a particular immunotherapeutic pro-”
BackgroundLi, S.-Y., Cheng, H., Qiu, W.-X., Zhang, L., Wan, S.-S., Zeng, J.-Y., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.026 · Cited by 260
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 256
Tallerico, R., Todaro, M., Di Franco, S., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P. N., La Rocca, R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201542 · Cited by 251
“Cancer may sometimes avoid such immunosurveillance through the outgrowth of nonimmunogenic tumor cell variants (immunoselection) and through subversion of the immune system (immunosubversion) (55).”
BackgroundHong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Garg, A. D., Dudek-Peric, A. M., Romano, E., & Agostinis, P. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150061pa · Cited by 240
“…immunosurveillance and antitumour immunity is achieved by various mechanisms including, acquaintance of low immunogenicity, ability to induce immunotolerance or active immunosuppression, and ability to resist immune cell-mediated lysis (Dunn et al., 2002, Garg et al., 2013b, Zitvogel et al., 2006).”
BackgroundIs interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy?
Apte, R. N., & Voronov, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00615.x · Cited by 239
Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types
Hong, I.-S. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.64 · Cited by 240
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.